Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of MK-4884 in Advanced/Metastatic Solid Tumors
jRCT2031260123Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of MK-4884 in colorectal cancer (CRC), clear cell renal cell carcinoma (ccRCC), non-small cell lung cancer (NSCLC) and 4 more, sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicities (DLT) and Adverse events (AEs). Started Jun 2026; status: recruiting.
02
Drugs
MK-4884
03
Conditions
colorectal cancer (CRC)clear cell renal cell carcinoma (ccRCC)non-small cell lung cancer (NSCLC)biliary cancerintrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on jRCT2031260123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260123.